Gothenburg, May 27, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, announces today that the company’s CEO, Jamal El-Mosleh, has sold approximately 12 percent of his total shareholding in the company. The sale was carried out for personal financial and tax-related reasons linked to the restructuring of ownership conducted last year, when the shareholding was transferred from a securities account to a capital insurance policy.
After the sale, Jamal El-Mosleh owns 2,712,200 shares and remains one of the company’s largest shareholders, with no plans for further sales in the near future. The transactions have been reported to the Swedish Financial Supervisory Authority’s insider register in accordance with applicable regulations.
“My strong belief in Elicera’s long-term value and our ongoing drug development programs, including the CARMA study, remains unchanged. As an insider, finding a suitable time for share transactions is always a challenge, and this sale was a necessary measure due to personal financial and tax-related reasons linked to a restructuring of my holdings from a securities account to a capital insurance policy. The sale should not be interpreted as a reflection of my view on the company’s future. I am still just as enthusiastic about continuing to develop Elicera as CEO and major shareholder,” says Jamal El-Mosleh, CEO of Elicera Therapeutics.
For further information, please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Advisor
Mangold Fondkommission AB
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.